Supplementary Table S5. Treatment abbreviations

|  |  |
| --- | --- |
| **Abbreviation** | **Definition** |
| 5FU | fluorouracil (5-FU) |
| 5FU+CIS | 5-FU plus cisplatin |
| 5FU+CIS+EPI | 5-FU plus cisplatin plus epirubicin |
| 5FU+GEM | 5-FU plus gemcitabine |
| ANL+CED | anlotinib plus cediranib |
| APT+GEMOX | apatinib plus gemcitabine plus oxaliplatin |
| ASC | active symptom control |
| BEV+GEM+IRI+CAP | bevacizumab plus gemcitabine plus irinotecan plus capecitabine |
| BIN+CAP | binimetinib plus capecitabine |
| BSC | best supportive care |
| CAP | capecitabine |
| CAP+CIS | capecitabine plus cisplatin |
| CAP+CYC+CEL | capecitabine plus cyclophosphamide plus celecoxib |
| CAP+MMC | capecitabine plus mitomycin C |
| CAP+PBO | capecitabine plus placebo |
| CAP+VAR | capecitabine plus varlitinib |
| CAR+PAC | carboplatin plus paclitaxel |
| CET+GEMOX | cetuximab plus gemcitabine plus oxaliplatin |
| DOCE | docetaxel |
| ERL | erlotinib |
| EVER | everolimus |
| FLUOR | fluoropyrimidine |
| FLUOR+IRI | fluoropyrimidine plus irinotecan |
| FOLFIRI | leucovorin plus 5FU plus irinotecan |
| FOLFIRI(m) | leucovorin plus 5FU plus irinotecan |
| FOLFIRI | leucovorin plus 5+FU plus nanoliposomal irinotecan |
| FOLFIRINOX | leucovorin plus 5FU plus irinotecan plus oxaliplatin |
| FOLFOX | leucovorin plus 5FU plus oxaliplatin |
| FOLFOX(m) | modified 5FU plus oxaliplatin |
| FOLFOX(m) | modified oxaliplatin plus 5FU chemotherapy  |
| FOLFOX(m)+ASC | modified 5FU plus oxaliplatin |
| FOLFOX3(m) | modified 5FU plus oxaliplatin |
| FOLFOX4 | leucovorin plus 5FU plus oxaliplatin |
| FOLFOX4 | leucovorin plus 5FU plus oxaliplatin |
| FUDR | intrahepatic fluorodeoxyuridine |
| GEM | gemcitabine |
| GEM+CAP | gemcitabine plus capecitabine |
| GEM+CIS | gemcitabine plus cisplatin |
| GEM+FLUOR | gemcitabine plus fluoropyrimidine |
| GEM+nabPAC | gemcitabine plus nab paclitaxel |
| GEMOX | gemcitabine plus oxaliplatin |
| GEM+PLT | gemcitabine plus platinum-based chemo |
| GEM+PLT | gemcitabine plus platinum doublet |
| GEM+S1 | gemcitabine plus S1 |
| iFAM | 5FU plus doxorubicin plus mitomycin C |
| IMAT | imatinib mesylate |
| INFG | infigratinib |
| IRI | irinotecan |
| IVO | ivosidenib |
| MIX (5FU) | 5+FU-based combination treatment |
| MIX (5FU/CAP) | 5+FU or capecitabine |
| MIX (5FU/IRI) | 5+FU or irinotecan |
| MIX (5FU+GEM/GEM+PLT) | 5+FU plus gemcitabine OR gemcitabine plus platinum |
| MIX (5FU+IRI/5FU+PLT) | 5+FU plus irinotecan OR 5+FU plus platinum-based chemotherapy  |
| MIX (5FU+LV/CAP) | 5FU plus leucovorin or capecitabine |
| MIX (5FU+PLT) | 5+FU plus platinum-based chemotherapy  |
| MIX (CAP-based) | capecitabine-based |
| MIX (FLUOR/FLUOR-based)+BSC | fluoropyrimidine or fluoropyrimidine-based chemotherapy plus best supportive care |
| MIX (FLUOR/FLUOR+PLT/FLUOR+IRI) | fluoropyrimidine monotherapy, fluoropyrimidine plus irinotecan, OR fluoropyrimidine plus platinum-based chemotherapy  |
| MIX (FLUOR-based) | fluoropyrimidine based  |
| MIX (FLUOR+PLT) | fluoropyrimidine plus platinum-based chemotherapy  |
| MIX (FOLFIRI/FOLFOX) | FOLFIRI or FOLFOX |
| MIX (FOLFIRI/FOLFOX/CIS+5FU) | leucovorin plus 5FU plus irinotecan OR leucovorin plus 5FU plus oxaliplatin OR cisplatin plus 5FU |
| MIX (FOLFIRI/XELIRI) | leucovorin plus 5FU plus irinotecan OR capecitabine plus irinotecan |
| MIX (FOLFIRI-based) | FOLFIRI based |
| MIX (FOLFOX/XELOX) | leucovorin plus 5FU plus irinotecan OR capecitabine plus oxaliplatin |
| MIX (GEM-based) | gemcitabine based |
| MIX (IRI-based) | irinotecan based |
| MIX (non–CAP-based) | non–capecitabine based  |
| MIX (PLT-based) | platinum based  |
| MIX (TAX-based) | taxane based |
| MIX (TGT TX) | targeted treatment OR single-agent chemotherapy with or without targeted treatment |
| MIX (XELOX/FOLFIRI/GEM+CAP/GEM+CIS/PAC+CET) | capecitabine plus oxaliplatin OR leucovorin plus 5+FU plus irinotecan OR gemcitabine plus capecitabine OR gemcitabine plus cisplatin OR paclitaxel plus cetuximab |
| MK2206 | MK2206 (investigational agent) |
| nab+PAC | nab-paclitaxel |
| NIV | nivolumab |
| Other [NS] | other treatments, not otherwise stated  |
| Other | various mixes of treatments |
| PBO | placebo |
| PEM | pembrolizumab |
| REG | regorafenib |
| S1 | tegafur plus gimeracil plus oteracil |
| SOR | sorafenib |
| SPI-1620+DOCE | SPI-1620 plus docetaxel |
| SUN | sunitinib |
| TAX | taxane |
| TGT | targeted molecular therapies, as monotherapy or in combination |
| TKI | tyrosine kinase inhibitors such as axitinib, lenvatinib, trametinib |
| TRAM | trametinib |
| XELIRI | capecitabine plus irinotecan |
| XELOX | capecitabine plus oxaliplatin |